Merck & Co.
United States
3790 articles with Merck & Co.
-
Pharma giant Merck announced it is expanding in both area and headcount with a new Cambridge, MA office. The company's plan is to add 160,000 square feet and 100 new employees.
-
Merck Announces Third-Quarter 2022 Dividend
5/24/2022
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.69 per share of the company’s common stock for the third quarter of 2022.
-
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breast Cancer at High Risk of Recurrence
5/24/2022
Merck, known as MSD outside the United States and Canada, announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced or early-stage triple-negative breast cancer at high risk of recurrence.
-
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
5/20/2022
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB or IIC melanoma and who have undergone complete resection.
-
U.K. researchers found that the first dose of any vaccine was linked with an initial 12.8% decrease in the odds of Long COVID.
-
Merck Recognized for Responsible Entrepreneurship in the Netherlands
5/19/2022
On May 19, the Embassy of the Kingdom of the Netherlands presented the 2022 Holland on the Hill Heineken Award to New Jersey-based biopharmaceutical company Merck in a ceremony at the Library of Congress in Washington, D.C. Richard DeLuca, Jr., Executive Vice President of Merck and President of Merck Animal Health, accepted the award on behalf of the company, known as MSD outside the United States and Canada.
-
Possibly reflecting the current Bear market, Berkshire Hathaway has walked away from its stake in both AbbVie and BMS.
-
Pfizer apparently hasn't begun any combination trials in human beings of Paxlovid, and no reported human tests are using the drug in combination with other therapies.
-
ICER recommended two out of three outpatient treatments for COVID-19 in today's market, singling out molnupiravir as having inadequate evidence that it is better than symptomatic care.
-
Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA® (pembrolizumab)
5/10/2022
Merck, known as MSD outside the United States and Canada, announced that data for six approved medicines and pipeline candidates in more than 25 types of cancer will be presented at the 2022 American Society of Clinical Oncology Annual Meeting in Chicago from June 3-7.
-
Could big pharma buy out much of the biotech industry? Yes, according to analysts. But that’s not likely to happen anytime soon.
-
Janssen discontinued the development partnership due to advancements made by other companies against the human papillomavirus and its own changing strategic priorities.
-
AUM Biosciences Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate AUM001 in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer
5/5/2022
AUM Biosciences announced that it has entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, a premier global research-intensive biopharmaceutical company, to evaluate AUM001 in combination with MSD’s anti-PD-1 therapy, KEYTRUDA, in a global Phase 2 trial in patients with microsatellite stable colorectal cancer.
-
Merck to Participate in Bank of America Securities 2022 Healthcare Conference
5/4/2022
Merck, known as MSD outside the United States and Canada, announced that Executive Vice President and Chief Financial Officer Caroline Litchfield will participate in a fireside chat at the live Bank of America Securities 2022 Healthcare Conference.
-
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer
4/29/2022
Merck, known as MSD outside the United States and Canada, announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of microsatellite instability-high or deficient mismatch repair tumors in adults.
-
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
4/29/2022
Merck, known as MSD outside the United States and Canada, announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent or metastatic cervical cancer in adults whose tumors express PD-L1.
-
IONOVA Announces Clinical Trial Collaboration with MSD to Evaluate INV-1120 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
4/29/2022
Shenzhen IONOVA Life Science Co., Ltd. announces today it has entered into a clinical trial collaboration agreement with MSD (Merck & Co., Inc., Kenilworth, NJ., USA) to evaluate clinical benefits of INV-1120, IONOVA's EP4 antagonist, in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for cancer treatment.
-
Gilead’s Veklury made massive profits, but as more vaccine boosters arrive and more people become immune to the virus, the future of the antiviral is in question.
-
Merck Announces First-Quarter 2022 Financial Results
4/28/2022
Merck, known as MSD outside the United States and Canada, announced financial results for the first quarter of 2022.
-
Merck held a conference call Thursday morning to discuss its Q1 2022 earnings. The company reported a 50% growth in revenue, increasing its worldwide sales to $15.9 billion.